PTAB invalidates Zytiga patent

In an inter partes review (IPR) proceeding, the U.S. Patent Trial and Appeal Board invalidated all 20 claims of U.S. Patent No. 8,822,438 covering prostate cancer drug Zytiga abiraterone acetate from

Read the full 317 word article

User Sign In